BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33344043)

  • 21. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
    Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
    Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.
    Olofsson R; Ny L; Eilard MS; Rizell M; Cahlin C; Stierner U; Lönn U; Hansson J; Ljuslinder I; Lundgren L; Ullenhag G; Kiilgaard JF; Nilsson J; Lindnér P
    Trials; 2014 Aug; 15():317. PubMed ID: 25106493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
    Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
    J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma.
    Varghese S; Xu H; Bartlett D; Hughes M; Pingpank JF; Beresnev T; Alexander HR
    Ann Surg Oncol; 2010 Jul; 17(7):1870-7. PubMed ID: 20221901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM.
    Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Gustavsson A; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
    Ann Surg; 2024 Feb; ():. PubMed ID: 38420778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma.
    Bronkhorst IH; Vu TH; Jordanova ES; Luyten GP; Burg SH; Jager MJ
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5370-8. PubMed ID: 22743317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment.
    Heusner TA; Antoch G; Wittkowski-Sterczewski A; Ladd SC; Forsting M; Verhagen R; Scheulen M
    Rofo; 2011 Dec; 183(12):1151-60. PubMed ID: 22033849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease.
    Achberger S; Aldrich W; Tubbs R; Crabb JW; Singh AD; Triozzi PL
    Mol Immunol; 2014 Apr; 58(2):182-6. PubMed ID: 24370793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
    Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.
    García-Mulero S; Alonso MH; Del Carpio LP; Sanz-Pamplona R; Piulats JM
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients.
    Johansson J; Kiffin R; Andersson A; Lindnér P; Naredi PL; Olofsson Bagge R; Martner A
    Front Oncol; 2018; 8():570. PubMed ID: 30560089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma.
    Chandrasekhar S; Perez M; Niaz Z; Ekram J; Lal N; Koly S; Cao B; Zager JS; Alomar M
    Cancer Control; 2024; 31():10732748241246898. PubMed ID: 38605434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Locoregional management of hepatic metastasis from primary uveal melanoma.
    Sato T
    Semin Oncol; 2010 Apr; 37(2):127-38. PubMed ID: 20494705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
    Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases.
    Toivonen P; Mäkitie T; Kujala E; Kivelä T
    Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):1-6. PubMed ID: 14691146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases.
    Szeligo BM; Ivey AD; Boone BA
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
    Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US
    Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
    Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
    Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated hepatic perfusion for liver metastases of malignant melanoma.
    Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
    Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence of macrophage and lymphocyte, but not dendritic cell, infiltration in posterior uveal melanomas, whilst cultured uveal melanomas demonstrate pluripotency by expressing CD68 and CD163.
    Woodward J; Sisley K; Reeves G; Nichols C; Parsons MA; Mudhar H; Rennie I
    Int J Exp Pathol; 2004 Feb; 85(1):35-43. PubMed ID: 15113392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.